No Data
No Data
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
EF Hutton Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $21
Express News | Os Therapies Announces Last Patient Enrolled in Ost-Her2 Osteosarcoma Phase 2B Clinical Trial Receives Last Treatment Dose
Paul Romness Discusses OS Therapies' IPO & Clinical Advancement | NYSE-A:OSTX
The Investing Authority to Host Breakout Session With OS Therapies LIVE on X
Brookline Capital Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $9
No Data